News
Hims & Hers Health ( NYSE: HIMS) priced its offering of $870M aggregate principal amount of 0.00% convertible senior notes due 2030 in a private offering to persons reasonably believed to be qualified ...
Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...
Hers is a telehealth company that offers products for hair loss, skin care, sexual health, and mental health. Hers offers both prescription and nonprescription products. A person wishing to ...
Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy ...
24/7 Wall St. on MSN3d
Hims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Read why HIMS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback